RAC 0.97% $1.54 race oncology ltd

Ann: Race investor briefing invitation, page-18

  1. 356 Posts.
    lightbulb Created with Sketch. 805
    In my opinion the main concern with the IND is about de-risking. Until we have an approved IND we can't run a trial in the US. Our original IND application was not approved, so it's obviously more than just a formality. I feel it's a significant box to have ticked and may also be viewed with enthusiasm by the market.

    Once we have IND approval we wouldn't need to start a trial immediately if it didn't make sense to do so, but at least we would have passed that regulatory hurdle.
    Last edited by KingBuzzo: 27/07/22
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.